Skip to content

US · RYTM · BIOTECHNOLOGY

Rhythm Pharmaceuticals, Inc. (RYTM) intrinsic value and stock valuation

$112.36as of 2026-11-21 · Mkt cap 7.59B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Rhythm Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values RYTM with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from RYTM’s statements →

Rhythm Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02116 rhythmtx.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$189.8M
20122025
Net income
-$-196.54M
20122025
Free cash flow
-$-116.63M
20122025
Total equity
$270M+10.1% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$189.8M$130.1M$77.4M$23.6M$3.15M
Operating income-$-192.02M-$-265.5M-$-184.36M-$-179.16M-$-170.06M
Net income-$-196.54M-$-260.6M-$-184.68M-$-181.12M-$-69.61M
EPSd-$-3.02M-$-4.27M-$-3.2M-$-3.48M-$-1.4M
Operating cash flow-$-115.67M-$-113.88M-$-136.16M-$-173.43M-$-146M
Capital expenditure-$-950K$0.00-$-50K-$-4.28M-$-5.43M
Free cash flow-$-116.63M-$-113.88M-$-136.2M-$-177.71M-$-151.44M
Total assets$480.2M$392.3M$332.8M$382.5M$329.5M
Total debt$3.99M$3.94M$1.26M$1.94M$2.55M
Net debt-$-50.31M-$-85.2M-$-58.82M-$-125.73M-$-56.7M
Total equity$270M$164.6M$169.8M$264.3M$284.2M
Cash and short-term investments$389M$320.6M$275.9M$333.3M$294.9M
Income statement
20252024202320222021
Revenue$189.8M$130.1M$77.4M$23.6M$3.15M
Cost of revenue$19.5M$13.4M$9.3M$2.13M$600K
Gross profit$170.3M$116.8M$68.1M$21.5M$2.56M
Research and development expenses$167.3M$238M$135M$108.6M$104.1M
Selling, general and administrative expenses$194.9M$144.3M$117.5M$92M$68.5M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$362.3M$382.3M$252.5M$200.7M$172.6M
Cost and expenses$381.8M$395.6M$261.8M$202.8M$173.2M
Interest income$15.3M$14.7M$14M$4.03M$450K
Interest expense$20.6M$20.6M$13.9M$5.2M$0.00
Depreciation and amortization$1.34M$1.56M$1.76M$1.67M$1.16M
Ebitda-$-174.12M-$-238.09M-$-168.46M-$-174.25M-$-68.45M
Operating income-$-192.02M-$-265.5M-$-184.36M-$-179.16M-$-170.06M
Total other income/expenses, net-$-4.03M$5.25M$240K-$-1.96M$100.5M
Income before tax-$-196.04M-$-260.26M-$-184.11M-$-181.12M-$-69.61M
Income tax expense$500K$350K$560K$0.00$0.00
Net income-$-196.54M-$-260.6M-$-184.68M-$-181.12M-$-69.61M
Weighted average shares outstanding$65M$61M$57.7M$52.1M$49.6M
Weighted average diluted shares outstanding$65M$61M$57.7M$52.1M$49.6M
Balance sheet
20252024202320222021
Cash and short-term investments$389M$320.6M$275.9M$333.3M$294.9M
Net receivables$26.1M$18.5M$14.9M$6.22M$1.02M
Inventory$25.8M$18.7M$8.62M$2.92M$110K
Total current assets$466.9M$374.2M$308.3M$354.2M$308.4M
Property, plant and equipment, net$4.15M$4.11M$2.12M$3.38M$4.33M
Goodwill and intangible assets$5.32M$6.17M$7.03M$7.88M$4.66M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$13.3M$18.1M$24.5M$28.3M$21.1M
Total assets$480.2M$392.3M$332.8M$382.5M$329.5M
Accounts payable$14M$12.3M$4.88M$4.8M$5.74M
Short-term debt$650K$0.00$770K$680K$610K
Deferred revenue$190K$1.29M$1.29M$1.43M$7M
Total current liabilities$105.9M$115.5M$55.2M$39.8M$43.4M
Long-term debt$3.34M$3.94M$490K$1.26M$1.95M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$104.2M$112.2M$107.8M$78.4M$1.95M
Capital lease obligations$3.99M$3.94M$1.26M$1.94M$2.55M
Total liabilities$210.2M$227.7M$163M$118.2M$45.4M
Common stock$70K$60K$60K$60K$50K
Retained earnings-$-1.35B-$-1.16B-$-894.74M-$-710.06M-$-528.94M
Accumulated other comprehensive income (loss)-$-800K-$-40K$130K-$-90K-$0.00
Total equity$270M$164.6M$169.8M$264.3M$284.2M
Total investments$334.7M$231.4M$215.8M$205.6M$235.6M
Total debt$3.99M$3.94M$1.26M$1.94M$2.55M
Net debt-$-50.31M-$-85.2M-$-58.82M-$-125.73M-$-56.7M
Cash flow statement
20252024202320222021
Net income-$-196.54M-$-260.6M-$-184.68M-$-181.12M-$-69.61M
Depreciation and amortization$1.34M$1.56M$1.76M$1.67M$1.16M
Stock-based compensation$66.8M$39.7M$32.6M$19.8M$20.8M
Change in working capital-$-970K$10.6M$4.81M-$-19.72M$1.9M
Accounts receivable-$-7.57M-$-3.65M-$-8.64M-$-5.2M-$-1.25M
Inventory-$-7.47M-$-10.12M-$-5.71M-$-2.81M-$-10K
Accounts payable$21.9M$21.9M$14.8M$1.54M$18.3M
Net cash provided by operating activities-$-115.67M-$-113.88M-$-136.16M-$-173.43M-$-146M
Investments in property, plant and equipment-$-950K$0.00-$-50K-$-4.28M-$-5.43M
Acquisitions, net$0.00$0.00$0.00$4M$100M
Net cash used for investing activities-$-137.15M-$-48.17M-$-5.67M$28M-$-62.16M
Common stock issued$237.9M$195.2M$48.9M$131.1M$161.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00-$-3.97M$0.00$0.00$0.00
Net cash used for financing activities$218M$191.2M$74.4M$213.8M$166.5M
Net change in cash-$-34.78M$29.2M-$-67.6M$68.4M-$-41.68M
Cash at end of period$54.8M$89.6M$60.4M$128M$59.6M
Operating cash flow-$-115.67M-$-113.88M-$-136.16M-$-173.43M-$-146M
Capital expenditure-$-950K$0.00-$-50K-$-4.28M-$-5.43M
Free cash flow-$-116.63M-$-113.88M-$-136.2M-$-177.71M-$-151.44M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Rhythm Pharmaceuticals, Inc.

        Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.

        CEO
        David Meeker
        Employees
        414
        Beta
        1.88

        Explore

        Frequently asked questions

        What is the intrinsic value of Rhythm Pharmaceuticals, Inc. (RYTM)?

        Rhythm Pharmaceuticals, Inc. (RYTM) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is RYTM undervalued?

        RYTM trades at a price of $112.36 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.